We are live on
!
Find out more
NA
Navellier & Associates Portfolio holdings
AUM
$960M
1-Year Est. Return
79.37%
This Quarter
Est. Return
-12.81%
1 Year Est. Return
+79.37%
3 Year Est. Return
+262.34%
5 Year Est. Return
+412.53%
10 Year Est. Return
+2,309.54%
AUM
$466M
AUM Growth
-$122M
(-21%)
Cap. Flow
-$33.7M
Cap. Flow
% of AUM
-7.23%
Top 10 Holdings %
Top 10 Hldgs %
19.61%
Holding
343
New
56
Increased
75
Reduced
115
Closed
70
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bunge Global
BG
|
+$11.6M |
| 2 |
Archer Daniels Midland
ADM
|
+$9.76M |
| 3 |
Costco
COST
|
+$6.59M |
| 4 |
First Trust Health Care AlphaDEX Fund
FXH
|
+$5.6M |
| 5 |
Eli Lilly
LLY
|
+$5.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
West Pharmaceutical
WST
|
+$16.9M |
| 2 |
Johnson Controls International
JCI
|
+$10.1M |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$7.93M |
| 4 |
Entegris
ENTG
|
+$7.86M |
| 5 |
Intuit
INTU
|
+$6.84M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Energy | 18.46% |
| 2 | Technology | 13.89% |
| 3 | Consumer Staples | 13.84% |
| 4 | Industrials | 12.91% |
| 5 | Materials | 10.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
326
United Therapeutics
UTHR
$25.8B
| – | – |
-3,348
| Closed | -$601K |
|
327
Wingstop
WING
$3.53B
| – | – |
-1,797
| Closed | -$211K |
|
328
Wipro
WIT
$19.6B
| – | – |
-129,150
| Closed | -$498K |
|
|
329
West Pharmaceutical
WST
$24B
| – | – |
-41,237
| Closed | -$16.9M |
|
330
Willamette Valley Vineyards
WVVI
$12.7M
| – | – |
-12,751
| Closed | -$115K |
|
331
XPEL
XPEL
$1.22B
| – | – |
-23,735
| Closed | -$1.25M |
|
332
Zoetis
ZTS
$32.4B
| – | – |
-9,998
| Closed | -$1.89M |
|
|
ACCS
333
ACCESS Newswire
ACCS
$25.6M
| – | – |
-15,809
| Closed | -$470K |
|
|
EVA
334
DELISTED
Enviva Inc.
EVA
| – | – |
-2,599
| Closed | -$206K |
|
|
TGH
335
DELISTED
Textainer Group Holdings limited
TGH
| – | – |
-48,415
| Closed | -$1.84M |
|
|
TWTR
336
DELISTED
Twitter, Inc.
TWTR
| – | – |
-6,815
| Closed | -$264K |
|
|
ISBC
337
DELISTED
Investors Bancorp, Inc.
ISBC
| – | – |
-28,902
| Closed | -$432K |
|
|
SVA
338
DELISTED
Sinovac Biotech, Ltd
SVA
| $0 | ﹤0.01% |
15,828
| – | – |
|
Similar funds
JVBC
LOAMU
MK
QIM
TFP
UWPG
FWM
RCIM
Navellier & Associates's Q2 2022 Portfolio in Review
As of Q2 2022, Navellier & Associates held 343 positions worth $466M, down 21% from $588M the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Navellier & Associates withdrew a net $33.7M in Q2 2022, closing 70 positions and reducing 115 holdings. Its most notable exit was West Pharmaceutical, an estimated $16.9M position sold in full.
By sector, the portfolio is most concentrated in Energy at 18% of assets, up from 11% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Navellier & Associates opened a new position in First Trust Health Care AlphaDEX Fund worth $5.36M.
- Navellier & Associates's largest Q2 2022 buy was First Trust Health Care AlphaDEX Fund: 52,000 shares worth $5.36M.
- Navellier & Associates added most to Bunge Global in Q2 2022, an estimated $11.6M increase.
- Navellier & Associates's biggest Q2 2022 reduction was AMN Healthcare, cutting an estimated $3.55M.
- Navellier & Associates fully exited West Pharmaceutical in Q2 2022, selling an estimated $16.9M.
- Navellier & Associates's ten largest holdings make up 20% of its $466M portfolio in Q2 2022.
- Navellier & Associates opened 56 new positions and closed 70 in Q2 2022.
- Navellier & Associates's portfolio value fell 21% quarter-over-quarter to $466M.
Based on Navellier & Associates's 13F filing for Q2 2022, filed 12 Aug 2022.